Psychedelic investment continues to ramp up
Funding for developing mental health treatments derived from psychedelic drugs continue to raise hundreds of millions. Just last month, companies working with the hallucinogens MDMA, psilocybin, and DMT raised at…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope your team of choice was victorious in last night’s sports ball match. Today, we talk about psychedelics, obesity, and production issues with generic drugs. We also discuss the ongoing issues of scientific misconduct that are springing up left and right in academia, and how universities are scrambling to keep up.
What's Your Reaction?
